Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene to acquire U.S. commercialization rights for HepaGam B

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Roundtable discussion to elevate awareness about the importance of biopreparedness

Roundtable discussion to elevate awareness about the importance of biopreparedness

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Universal Detection signs deal with U.S. to become Featured U.S. Exporter of bioterrorism monitoring equipment in France

Universal Detection signs deal with U.S. to become Featured U.S. Exporter of bioterrorism monitoring equipment in France

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Non-human primate study results of Restanza released

Non-human primate study results of Restanza released

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

Universal Detection Technology to showcase its TS-10-5-agent biodetection kit

Universal Detection Technology to showcase its TS-10-5-agent biodetection kit

FDA grants orphan drug status to Advanced Life Sciences' Restanza

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Inactivation of ClpX gene may help treat anthrax poisoning

Inactivation of ClpX gene may help treat anthrax poisoning

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.